Acoramidis has potential for treating transthyretin amyloid cardiomyopathy, according to a trial.

Published Date: 30 Aug 2023

Acoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in comparison to placebo, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How access to specialized cancer centers affects glioblastoma outcomes

2.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

3.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

4.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

5.

Beyond What Is Visible in Myelofibrosis?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot